 |
|
|
|
|
|
|
|
|
|
|
 |
|
|||||||||
 |
 |
 |
 |
 |
 |
 |
 |
|
||
 |
 |
 |
|
|||||||
 |
|
|||||||||
 |
|
|||||||||
Alert Number 126
Date: September 16, 2024
We reviewed the GenMab Phase I / II clinical trial using their new improved anti-CD20 monoclonal drug in relapsed or refractory CLL patients. You can read the details in Sons of Rituxan and Campath and HuMax-CD20 - Improved Anti-CD20 Therapy?.
As we expected, enrollment in this trial was sold out in near record time. Some of us were disappointed at not being able to get in. But all of us are keeping our fingers crossed and rooting for the success of this one. The excitement is simply due to this: can we keep the low toxicity of Rituxan, since this drug too targets the same CD20 marker found only on mature B-cells, and because of better engineering improve the efficacy of the drug? Will HuMax-CD20 give us better bang for the buck? The company is publishing their results in the International World conference on CLL (IWCLL), September 16-18, 2024. You know me, I hate waiting. Here is the bottom-line scoop on the GenMab results.
I will be doing a full article on these results and other details of the GenMab paper in the next day or so. For now, the results are encouraging. Remember, these are relapsed and/or refractory patients, most of them had been through Rituxan and fludarabine prior to enrolling in this trial. In this crowd one would not expect too many CRs with plain vanilla Rituxan as single agent. Therefore, I am pleased that approximately one quarter of the patients got a CR. Not bad. But the devil is in the details, and you have to hold your horses for the next day or so. Today, I have to run some errands.
Be well,
Chaya
____
NOTICE: This page from the Topics Alert archive was originally emailed to subscribers of Topics Alert, a free service of CLL Topics Inc. If you are not a subscriber and you wish to receive email Alerts, please register at the Topics Alert subscription page. The content of this page is intended for information only and it is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
———
Disclaimer: The content of this website is intended for information only and is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
Copyright Notice:
Copyright © 2024-2007 CLL Topics, Inc. All Rights Reserved.
All materials contained on this site are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, published or broadcast without the prior written permission of CLL Topics, Inc. You may not alter or remove any trademark, copyright or other notice from copies of the content.
However, you may download and print material from CLLTopics.org exclusively for your personal, noncommercial use.
———
